English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aims: To determine the presentation, characteristics and associated co-morbidities in Nigerian men with prostate cancer. Study Design: Retrospective study. Place and Duration of Study: The study was carried at the Division of Urology, Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria from January 2010 to December 2018. Methodology: Men with histologically confirmed prostate cancer were analyzed. The age of the men, PSA pattern, histologic type, Gleason score, stage of the disease, associated co-morbidities and treatment received by the men were recorded. The effect of co-morbidities on disease aggressiveness using Gleason score and PSA as determinants was determined using Pearson correlation. SPSS version 23 was used in analyzing the data. P-value of < 0.05 was considered significant. Results: Eighty-one patients with prostate cancer from 2010 to 2018 were involved in the study. The mean age was 67.58±9.42 years with a range of 42 to 96years. Men with PSA >100 ng/ml had the highest frequency (34.60%). The mean Gleason Score was 6.28±2.13. Gleason score 7-8 had the highest frequency (35.8%). Seventy-nine patients (97.5%) had adenocarcinoma. EightyOriginal Research Article Ofoha and Magnus; JAMMR, 31(5): 1-7, 2019; Article no.JAMMR.52918 2 one percent of the men had advanced Pca, 58% being metastatic disease. 48.1% had comorbidities, 39.5% had hypertension, while 8.6% had both hypertension and diabetes. Comorbidities showed no correlation with PSA level (r=0.346), (p-value 0.375) and Gleason score (r=0.194), (p-value 0.639). Seventy-nine percent of the men had androgen deprivation therapy. Conclusion: Most of the men presented with advanced disease, with all indices pointing towards lethal disease. The commonest co-morbidity was hypertension and co-morbidities had no relationship with the aggressiveness of prostate cancer. To ensure early presentation and prevent lethal forms of Pca, health education, screening, counselling for men in the high-risk group is paramount.

Presentation, Characteristics and Co-morbidities of Men with Prostate Cancer in Nigeria